Skip to content
All Podcasts – Lifestyle
Author:
Rezolute, Inc.
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
September 24, 2026
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
September 9, 2026
Rezolute to Participate in Upcoming Investor Conferences
September 2, 2026
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
July 21, 2026
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
June 17, 2026
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
June 4, 2026
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
June 2, 2026
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
May 12, 2026
Rezolute to Participate in Upcoming Investor Conferences
May 11, 2026
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
May 1, 2026
1
2
Next Page
→